enCore Energy Announces Continued Positive Uranium Extraction Rates; Promotes Mr. Dain McCoig to Chief Operating Officer
DALLAS, July 28, 2025 /CNW/ - enCore Energy Corp. (NASDAQ:EU| TSXV: EU) (the "Company" or "enCore"), America's Clean Energy Company TM, today announced the promotion of Mr. Dain McCoig from Senior Vice-President to Chief Operating Officer. Mr. McCoig has proven to be an outstanding leader having led the team in orchestration and implementation of the Company's dramatic increase in production at the Atla Mesa In-Situ Recovery ("ISR") Uranium Central Processing Plant ("CPP") since early March 2025. The Company has substantially increased the number of drill rigs turning in South Texas while significantly shortening the installation time for new injection and extraction wells at Wellfield 7. These team efforts have resulted in more than a doubling of uranium extraction rates since he took over leadership of the operations team.
The Company is pleased to report the following operational updates from the Alta Mesa Project:
2025 Uranium Extraction Rates (lbs U 3 O 8)
June
80,346
May
65,188
April
58,263
March
67,817
February
30,352
January
15,647
Q2/25 Output: 203,797 lbs of uranium (U 3 O 8) extracted at Alta Mesa in Q2, up from 113,816 pounds extracted in Q1;
Q2/25 Wellfield development continues to expand at an accelerated rate with 75 new wells (35 extraction and 40 injection) installed in Wellfield 7 during the quarter;
25 drill rigs are now active in South Texas with expected increases to 30 rigs during August 2025;
Continued upgrading of the electrical system controlling wellfield operation, resulting in fewer and shorter operational interruptions;
Continued advancement of drilling in advance of wellfield installations in Wellfield 7;
Delineation and monitor well drilling for application of permit amendment for Wellfield 3 extension.
William M. Sheriff stated: "This is a well-earned and exciting advancement for Dain, who has been instrumental in leading and transforming our operations and expanding our uranium extraction rates. His steady leadership, deep technical expertise, and relentless focus on safety, efficiency, and execution have been essential to enCore's success and growth. From building out our operational capabilities at Rosita and Alta Mesa, to driving innovation, Dain has consistently demonstrated the vision and discipline that define great leadership. His ability to align field performance with corporate strategy has been critical as we've scaled our operations and positioned ourselves as a leading U.S. ISR uranium extraction company."
Dain McCoig Chief Operating Officer
Mr. McCoig is a seasoned engineering and operations leader with over 18 years of experience in mining, mineral processing, and facility development. As Director of Operations at enCore Energy Corporation, he supported uranium recovery operations across engineering, geology, and regulatory functions—driving performance, cost-efficiency, and providing technical excellence. Serving as Senior Vice President since March 2025, Mr. McCoig demonstrated superior ability to lead the team to effectively and efficiently increase uranium extraction rates at the South Texas operations while expanding his role to oversee project development activities throughout the organization.
Previously, Mr. McCoig served as Vice President of Operations at Alabama Graphite Products, where he led the engineering, construction, and team development for a $200M battery-grade graphite facility. Prior to this, he held several leadership roles at URI, Inc., managing uranium production, site restoration, and early-stage project planning, while coordinating with regulators, landowners, and stakeholders.
A licensed Professional Engineer in Texas and Alabama, Dain holds a B.S. in Engineering from the Colorado School of Mines and is pursuing his MBA at Auburn University. He is actively involved in industry groups including SME and various mining associations.
About the Alta Mesa ISR Uranium CPP and Wellfield ("Alta Mesa Uranium Project")
The Alta Mesa Uranium Project hosts a fully licensed and constructed ISR Central Processing Plant and operational wellfield located on 200,000+ acres of private land and mineral rights in and regulated by the state of Texas. Total operating capacity at the Alta Mesa CPP is 1.5 million pounds. uranium per year with additional drying capacity of 0.5 million pounds. The Alta Mesa Uranium Project operates under a 70/30 joint venture with Boss Energy Limited (ASX: BOE; OTCQX: BQSSF) that is managed by the Company.
The Alta Mesa CPP historically produced nearly 5 million pounds. of uranium between 2005 and 2013 when production was curtailed as a result of low prices. The Alta Mesa Uranium Project utilizes well known ISR technology to extract uranium in a non-invasive process using natural groundwater and oxygen. Currently, oxygenated water is being circulated in the wellfield through injection or extraction wells plumbed directly into the primary pipelines feeding the Alta Mesa CPP. Expansion of the wellfield will continue, with extraction to steadily increase from the wellfield as expansion continues through 2025 and beyond.
The Company also announces that Ms. Shona Wilson, Chief Financial Officer, will be leaving the organization following the filing of the 10Q in August. Ms. Wilson has been a dedicated and valued member of our team, and we are grateful for the contributions she has made during her time at enCore. With expanding operations at the Company, enCore has been conducting an active search for the Chief Financial Officer position with an emphasis on commodity production, U.S. public company operations and deep experience in SOX compliance. enCore has narrowed the search to a small list of highly qualified individuals and expects to announce the successful candidate in the coming weeks.
John M. Seeley, Ph.D., P.G., C.P.G., enCore's Chief Geologist, and a Qualified Person under NI 43-101 and Regulation S-K subpart 1300 of the Exchange Act of 1933 as amended, has reviewed and approved the technical disclosure in this news release on behalf of the Company.
About enCore Energy Corp.
enCore Energy Corp., America's Clean Energy Company™, is committed to providing clean, reliable, and affordable fuel for nuclear energy as the only United States uranium company with multiple Central Processing Plants in operation. The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore solely utilizes ISR for uranium extraction, a well-known and proven technology co-developed by the leaders at enCore.
Following upon enCore's demonstrated success in South Texas, future projects in enCore's planned project pipeline include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming. The Company holds other assets including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impact from corporate developments.
Cautionary Note Regarding Forward Looking Statements:
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws that are based on management's current expectations, assumptions and beliefs. Forward-looking statements can often be identified by such words as " will", " expects", " plans", "believes", " intends", "estimates", "projects","continue", "potential", and similar expressions or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results " may", " could", or " will" be taken.
Forward-looking statements and information that are not statements of historical fact include, but are not limited to, any statements regarding future expectations, beliefs, goals or prospects, statements regarding the preliminary second quarter results and intent to engage a national law firm. All such forward-looking statements are not guarantees of future results and forward-looking statements are subject to important risk factors and uncertainties, many of which are beyond the Company's ability to control or predict, that could cause actual results to differ materially from those expressed in any forward -looking statement. A number of important factors could cause actual results or events to differ materially from those indicated or implied by such forward-looking statements, including, exploration and development risks, changes in commodity prices, access to skilled personnel, the results of exploration and development activities; extraction risks; uninsured risks; regulatory risks; defects in title; the availability of materials and equipment, timeliness of government approvals and unanticipated environmental impacts on operations; litigation risks; risks posed by the economic and political environments in which the Company operates and intends to operate; increased competition; assumptions regarding market trends and the expected demand and desires for the Company's products and proposed products; reliance on industry equipment manufacturers, suppliers and others; the failure to adequately protect intellectual property; the failure to adequately manage future growth; adverse market conditions, the failure to satisfy ongoing regulatory requirements and factors relating to forward looking statements listed above which include risks as disclosed in the Company's filings on SEDAR+ and with the Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, management discussion and analysis and annual information form. Should one or more of these risks materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. The Company assumes no obligation to update the information in this communication, except as required by law. Additional information identifying risks and uncertainties is contained in filings by the Company with the respective securities commissions which are available online at www.sec.gov and www.sedarplus.ca.
Forward-looking statements are provided for the purpose of providing information about the current expectations, beliefs and plans of management. Such statements may not be appropriate for other purposes and readers should not place undue reliance on these forward-looking statements, that speak only as of the date hereof, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 hours ago
- Globe and Mail
3 Unstoppable Stocks to Buy in August
Key Points Investors have multiple reasons to like AbbVie stock. Eli Lilly remains a top stock to buy and hold. Vertex Pharmaceuticals is moving quickly to expand its markets beyond cystic fibrosis. 10 stocks we like better than AbbVie › The "it" factor. Some stocks have it. Other stocks don't. But the ones that do can be virtually unstoppable. Three Motley Fool contributors believe they've found such unstoppable stocks with the "it" factor to buy in August -- and they're all in the healthcare sector. Here's why they picked AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). There are many reasons to buy this stock Prosper Junior Bakiny (AbbVie): It's been a little over two years since AbbVie lost patent exclusivity for its best-selling drug, autoimmune disease medicine Humira. That didn't stop AbbVie, though; it just slowed it down momentarily. The company rebounded nicely and has since returned to top-line growth. AbbVie now owns another one of the top-10 selling therapies in the world, Skyrizi, which targets several immunology conditions. Skyrizi's sales have been growing at an incredibly rapid rate. Together with Rinvoq, AbbVie's immunology lineup has successfully filled the gap left by Humira. That's an important reason to consider the stock: AbbVie's ability to overcome a significant patent cliff speaks volumes about its innovative abilities. Beyond that, AbbVie's lineup is deep. It features older products that continue to make meaningful contributions to its financial results, such as its Botox franchise, and newer products that can help drive top-line growth for a while, like migraine treatment Qulipta. AbbVie's pipeline also looks deep. The company should be able to record consistent clinical and regulatory wins. Lastly, we can't mention AbbVie without pointing out its incredible dividend track record. The company is part of the exclusive group of Dividend Kings, boasting an active streak of 53 consecutive payout increases, which includes the time it spent as a division of its former parent company, Abbott Laboratories. AbbVie's forward yield of 3.5% is much higher than the S&P 500 's average of 1.3%, and its cash payout ratio looks reasonable at 61.8%. In addition to an excellent underlying business, a strong lineup, and a solid pipeline, AbbVie is an outstanding stock for income-seeking investors. Investing in this company could yield superior returns over the long term. Eli Lilly is a top growth stock to own for years David Jagielski (Eli Lilly): A stock that looks unstoppable right now is Eli Lilly. While many investors will focus on its highly successful GLP-1 drugs, Zepbound and Mounjaro, as the main reasons to invest in the business, there's much more behind the company, and why it's a top growth stock. Eli Lilly has a promising Alzheimer's treatment, Kisunla, which regulators approved for use last year. It's still in the early innings of its growth and according to analysts, it could generate up to $5 billion in annual revenue at its peak. Meanwhile, Eli Lilly is still focusing on developing more life-changing treatments for patients. It's planning to invest $4.5 billion into a research and manufacturing facility, which it calls Lilly Medicine Foundry. By utilizing new manufacturing methods to ensure high efficiency, the new center can help the company scale and bring new products to market faster. The company also has vast resources at its disposal, which can help it invest in research and development and potentially acquire promising businesses along the way. In the trailing 12 months, Eli Lilly has generated $11.1 billion in profit on sales totaling $49 billion. The company's terrific margins, strong growth prospects, and commitment to producing new treatments are why this pharmaceutical stock can be among the best investments you can put in your portfolio right now. A big biotech innovator that's targeting new markets Keith Speights (Vertex Pharmaceuticals): To truly be unstoppable, a company can't have competition that could, well, stop it. Vertex Pharmaceuticals has this covered with its cystic fibrosis (CF) franchise. No other drugmaker has approved therapies that treat the underlying cause of CF. The number of companies with experimental CF therapies in late-stage clinical testing that could compete with Vertex totals... zero. Actually, Vertex's biggest rival in treating CF is itself. The company's newest CF therapy, Alyftrek, offers a more convenient once-per-day dosing than its current top-seller, Kaftrio/Trikafta. However, CF isn't the main reason why I like Vertex. My primary interests lie with other indications the biotech innovator is targeting. For example, Vertex won U.S. regulatory approval for Journavx earlier this year. It's the first new class of pain medication in over 20 years. Journavx is safe and effective, with none of the side effects and addictive potential associated with opioids -- because it isn't an opioid. The company's pipeline features promising late-stage programs that could further expand Vertex's market opportunity. Inaxaplin targets APOL1-mediated kidney disease, which affects around 250,000 patients worldwide. Povetacicept holds the potential to treat multiple kidney diseases, with IgA nephropathy first on the list with a patient population of over 1 million. Zimislecel could cure severe type 1 diabetes. At first glance, Vertex might seem to be priced at a premium, with its shares trading at 26.3 times forward earnings. However, the company's growth prospects are so strong that its valuation is attractive. Vertex's price-to-earnings-to-growth (PEG) ratio, based on analysts' five-year earnings growth estimates, is a super-low 0.58. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in AbbVie and Vertex Pharmaceuticals. Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
Globe and Mail
6 hours ago
- Globe and Mail
3 Dividend Stocks to Hold for the Next 20 Years
Key Points General Mills is offering a historically high yield backed by a powerful and diversified food business. PepsiCo is a Dividend King with a high yield and iconic global brands. Hershey makes an affordable luxury that people will be willing to pay up for. 10 stocks we like better than PepsiCo › Remember one thing when you consider consumer staples makers: You "need" the products they sell. That's particularly true when it comes to food-focused consumer staples companies like General Mills (NYSE: GIS), PepsiCo (NASDAQ: PEP), and Hershey (NYSE: HSY). Here's why each one of these dividend stocks is worth buying and holding for 20 years, or more, right now. 1. General Mills is shifting with the times General Mills makes food products like cereal, snack bars, pet food, and baking products. It owns a collection of brand names that you likely know well, including Blue Buffalo and Cheerios. The brands and products it sells are staples in grocery stores and in consumer cupboards. It's highly unlikely that General Mills will suddenly go out of business anytime soon. That said, right now the company is facing some headwinds. Consumer buying habits are shifting, and some buyers are pulling back on spending. That has left General Mills' financial results weak. Sales and earnings fell year over year in the fourth quarter of fiscal 2025. The company's fiscal 2026 outlook was a bit weak, too. But management is doing what it can to adjust, including changing formulations to match current trends, adjusting its brand and product portfolio, and trying to keep a lid on costs. These are the right moves and, in time, they will likely lead to General Mills getting back on track. It always has in the past. While General Mills' stock is out of favor, you can buy it at an attractive 4.8% yield. That's near the highest levels in the company's history. If you like income and think long term, General Mills should probably be on your buy list today. 2. PepsiCo has industry-leading brands General Mills is a good company with industry-leading brands, but PepsiCo's brands stand out even more. It's the No. 2 beverage company and the No. 1 salty snack maker. It also makes packaged food products that compete with companies like General Mills. The problem for PepsiCo is that customer tastes are shifting, and it is out of step with its customers. The company is working on the issue -- it recently bought a Mexican-American food business and a probiotic beverage company. Both are more in line with current trends. Sure, PepsiCo's recent financial results aren't that great, and they lag those of its closest peers. It's OK -- that happens even to well-run businesses. PepsiCo didn't achieve Dividend King status by accident, and it has muddled through hard times before. It's highly likely that it will do so again. In the meantime, you can collect a historically high 3.9% dividend yield. If the dividend history here is any guide, you'll end up a long-term winner if you're willing to step in while the rest of Wall Street is selling. 3. Hershey's cocoa problem makes it hard to love Hershey is the most difficult story to appreciate here for two reasons. First, while it makes food, the most important product it sells is chocolate. That's not a necessity, even though people love the affordable indulgence. Second, the biggest headwind for the business is a shocking rise in the price of cocoa, a key ingredient in chocolate. Cocoa comes from trees, so it could take some time before high prices lead to changes in the industry. That's why investors have sold Hershey stock hard, leading to a historically high 2.9% dividend yield. Just how bad is it? Despite increasing prices and the expectation of sales growth in 2025, Hershey is projecting rising costs to lead to a roughly mid-30% drop in earnings in 2025. And given the nature of cocoa, the pain could linger for a bit. There's a good reason why investors are negative on the stock. But if you can stomach some near-term uncertainty, the long-term picture is likely to be continued and growing demand for the affordable luxuries that Hershey sells. You need and want what they make It is hard to suggest that chocolate, soda, or cereal are life necessities. You can certainly eat and drink other things. But these consumer staples giants have long delivered the food items that people want to buy. That will be just as true in one year as it is in 10 years or 20 years. The headwinds they face today aren't likely to change anything about the nature of these businesses, even if the companies do need to adjust to better align with current trends. The truth is that they've all done that many times before. Given the historically high yields on offer from General Mills, PepsiCo, and Hershey, buying and holding for decades is probably a good call for even the most conservative dividend investors today. Should you invest $1,000 in PepsiCo right now? Before you buy stock in PepsiCo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and PepsiCo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
6 hours ago
- Globe and Mail
Here's How Alphabet Can Become the World's Second $4 Trillion Company
Key Points The company generates the most profits among its big tech peers. Investors are worried about the legacy search business. But Alphabet has proven that it's here to stay. 10 stocks we like better than Alphabet › Nvidia made history by becoming the world's first $4 trillion company, and no other company has achieved this feat. Currently, Microsoft and Apple are in second and third place but have a bit of work to do with their $3.8 trillion and $3.2 trillion market caps, respectively. However, there's a dark horse that could beat those two to the $4 trillion threshold: Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL), the world's fifth-largest company by market cap with a valuation of $2.5 trillion. That's a long way away from $4 trillion and significantly behind Microsoft and Apple. But there's one factor that Alphabet has going for it that gives it a solid argument for reaching $4 trillion before any of the companies ahead of it. Alphabet's second quarter was dominant Alphabet is likely better known by the businesses that it owns: Google, YouTube, Waymo, and the Android operating system. It has a dominant empire in various niches, but its most important is Google Search. In the second quarter, Google Search generated $54 billion of the company's revenue of $96 billion. That's a large chunk of its total, so it needs to continue having this division perform well to succeed as a whole. However, there are some early warning signs that have investors concerned. The most significant technologies in generative artificial intelligence (AI) have the potential to transform how people use the internet. Currently, the vast majority of people seek information using Google Search. That could change if generative AI becomes more widely adopted by the masses. The market broadly assumes that it will replace Google, but that seems far from reality. One area where Google has bridged the gap is with AI search overviews, which give users a generative AI-powered summary of their search results. Management discussed the popularity of this feature during its second-quarter conference call and provided a couple of key insights for investors. First, AI overviews now have over 2 billion users in 40 different languages, showcasing its widespread appeal. Another huge revelation for investors is that it sees the same monetization as regular search results, so it's not harming Google's business at all by heavily investing in this technology. This showed up in Alphabet's results, as Google Search revenue rose 12% year over year. That's an acceleration from the 10% year-over-year growth in the first quarter. This isn't a sign of a dying business; it's a sign of one that's growing. As a result, there's no reason for Alphabet to trade at a significant discount to its big-tech peers, since it's growing just as fast (if not faster) than most of them. Its peers fetch a much higher premium The four companies ahead of Alphabet in market cap are Nvidia, Microsoft, Apple, and Amazon. Compared to these four, Alphabet trades at a huge discount. GOOGL PE Ratio data by YCharts; PE = price to earnings. However, over the past 12 months, Alphabet has produced the most net income of any of these companies. GOOGL Net Income (TTM) data by YCharts; TTM = trailing 12 months. Alphabet actually produces the most profit of any company that trades on U.S. exchanges, and if it received the same multiple as its peers, it would be the largest company in the world (in some cases). Company Trailing P/E Alphabet's Valuation at That Premium Nvidia 56.0 $6.47 Trillion Microsoft 39.7 $4.59 Trillion Apple 33.3 $3.85 Trillion Amazon 37.7 $4.36 Trillion Data source: YCharts. So, if the company were to receive the same respect as its peers, it would already be the world's largest company. Whether you think most of the big tech stocks are overvalued or if you think Alphabet is undervalued, it doesn't matter. It has some of the best chances of beating the market over the next few years due to its low valuation and impressive growth, considering its size. I think it's a top stock to buy now, and it makes even more sense if you're concerned that the market in general is getting too expensive. Should you invest $1,000 in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Keithen Drury has positions in Alphabet, Amazon, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
